Chapter 6 186 2C). Half of study participants (49.6%) reported no dyspnoea throughout follow-up. In the trajectory with the highest proportion of participants with dyspnoea during the first month of illness (24.0%), a steady improvement (decrease in reporting dyspnoea) was observed over the two-year period (Figure 2D). Supplementary Tables S3-S6 show the determinants of belonging to each trajectory of fatigue, loss of smell and/or taste, myalgia and dyspnoea. When adjusting for age, sex and BMI, individuals infected on or after 1 June 2020 had significantly lower odds of experiencing moderate, chronic loss of smell/taste compared to no loss of smell/taste, than individuals infected during the first wave. Figure 2. Group-based trajectories based on the proportion reporting fatigue (A), loss of smell and/or taste(B), myalgia (C), or dyspnoea (D) at 2-24 months after illness onset, adjusted for age (years), sex, BMI category and timing of infection (first wave vs. subsequent waves) Long COVID symptoms were defined as those developing within 1 month of overall illness onset, in order to exclude sporadic symptoms that were less likely to be attributed to the consequences of COVID-19. Central shape denotes mean proportion of participants reporting the specific symptom; dashed lines represent the 95% confidence interval. Percentages in legend show the proportion of study participants belonging to the trajectory.
RkJQdWJsaXNoZXIy MTk4NDMw